MSH2 and non-small cell lung carcinoma: Nevertheless, in the case of non-small-cell lung cancer (NSCLC), a better response to ICB was reported among patients harboring mutations in a series of genes implicated in DNA replication and repair as POLD1, POLE, MSH2, DNA-PK and RAD17It (41).